CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) insider Naimish Patel sold 3,150 shares of the firm's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares in the company, valued at $634,281.18. The trade was a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
CRISPR Therapeutics Price Performance
Shares of NASDAQ:CRSP opened at $50.09 on Wednesday. The stock's 50-day moving average is $53.80 and its 200 day moving average is $57.24. The company has a market cap of $4.81 billion, a PE ratio of -7.68 and a beta of 1.72. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to analysts' expectations of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The company's quarterly revenue was down 97.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.01) EPS. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on CRSP shares. Morgan Stanley reaffirmed an "underweight" rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. TD Cowen boosted their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a "hold" rating in a research report on Friday, February 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Chardan Capital raised their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a "buy" rating in a report on Saturday, February 14th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $64.53.
Check Out Our Latest Report on CRISPR Therapeutics
Trending Headlines about CRISPR Therapeutics
Here are the key news stories impacting CRISPR Therapeutics this week:
- Positive Sentiment: Piper Sandler reaffirmed an "overweight" rating and raised its price target to $110, implying material upside and signaling stronger analyst confidence in CRSP's clinical and commercial prospects. Read More.
- Neutral Sentiment: CRISPR completed a $600 million private convertible notes offering on March 16 that boosts near-term liquidity and funding flexibility for R&D/operations but could lead to future dilution if notes convert. Investors will weigh cash runway benefits against potential dilution and interest/convertible terms. Read More.
- Negative Sentiment: CEO Samarth Kulkarni sold 10,349 shares at an average $48.26 on March 16 (~$499k), reducing his stake by ~4.04%; the sale was disclosed in an SEC filing. Insider selling can be read as profit-taking or diversification and may raise short-term investor concern. Read More.
- Negative Sentiment: General Counsel James Kasinger sold 3,450 shares at an average $48.26 (~$166k) on March 16, decreasing his stake by ~3.64%; disclosed in an SEC filing. Additional insider sales add to near-term bearish signaling. Read More.
- Negative Sentiment: Insider Naimish Patel sold 3,150 shares at an average $48.26 (~$152k) on March 16, cutting his position by ~19.33%; the sale was reported in an SEC filing. Multiple insiders selling on the same date strengthens the perception of distribution risk for some traders. Read More.
Institutional Trading of CRISPR Therapeutics
A number of hedge funds have recently modified their holdings of the business. GSK plc purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $168,890,000. Orbis Allan Gray Ltd lifted its position in CRISPR Therapeutics by 76.9% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company's stock valued at $134,467,000 after acquiring an additional 1,201,600 shares during the period. Geode Capital Management LLC lifted its position in CRISPR Therapeutics by 98.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company's stock valued at $100,789,000 after acquiring an additional 1,025,979 shares during the period. SR One Capital Management LP boosted its stake in CRISPR Therapeutics by 94.4% during the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company's stock worth $132,132,000 after acquiring an additional 989,812 shares in the last quarter. Finally, State Street Corp grew its holdings in CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company's stock worth $159,082,000 after purchasing an additional 859,334 shares during the period. Institutional investors own 69.20% of the company's stock.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
